Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.
about
Age-specific distributions of cytogenetic subgroups of acute myeloid leukemia: data analysis in a Chinese population.Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.Demographic and prognostic factors of 455 patients with acute leukemia admitted to two referral hospitals in tehran-iran during ten years (2001-2011).CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts.Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.High DNA-methyltransferase 3B expression predicts poor outcome in acute myeloid leukemia, especially among patients with co-occurring NPM1 and FLT3 mutations.Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy.Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia.MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report.Clinical and pathological features of myeloid leukemia cutis.
P2860
Q30582619-5EABCC1F-BBBA-4E99-B28B-4902822851A6Q33774504-8B049489-D17C-4865-A9E7-5F1C3057E475Q34959094-13EEB3F8-6147-447D-8905-A4024165CBE9Q36305952-28CCA2A3-0810-44E1-957F-5401435DD0F2Q36558219-0FB64431-DE37-4409-B369-5D5C47D7E888Q38183943-820DC31E-8CCB-4346-9EB1-56B815F34388Q39601810-627D993D-8EC3-4F14-8133-98AA9BBDEE6FQ42974502-7AF6F6DC-7A59-474F-9CAA-CD0EB11B30EEQ43798520-A1D7F12C-BFC0-4B1F-A3C8-133D10296868Q45132395-82B9EA52-D568-4D8E-8655-78279C6BF107Q48568744-A957ECF9-CB1A-4282-983B-226CBC3DA97DQ50883085-803AE69A-78E2-4737-A973-ACB0625E3092Q51760643-556F6FFC-90B3-4233-A05C-2AC3C47B096FQ54979825-1109C9F9-A460-40CB-863F-5B2F4E3DA381
P2860
Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Prognostic impact of white blo ...... of mutated NPM1 and FLT3-ITD.
@en
type
label
Prognostic impact of white blo ...... of mutated NPM1 and FLT3-ITD.
@en
prefLabel
Prognostic impact of white blo ...... of mutated NPM1 and FLT3-ITD.
@en
P2093
P2860
P1433
P1476
Prognostic impact of white blo ...... of mutated NPM1 and FLT3-ITD.
@en
P2093
Edo Vellenga
Eveline S J M de Bont
Gert Ossenkoppele
Gerwin Huls
Hendrik J M de Jonge
Jan Jacob Schuringa
Peter J M Valk
P2860
P304
P356
10.3324/HAEMATOL.2011.040592
P577
2011-05-23T00:00:00Z